0

Close
 
Upcoming Allied Market Research
2023
Drug Delivery Technology Market

Drug Delivery Technology Market

by Type (Oral Route, Parenteral Route, Transdermal Route, Inhalation Route, Nasal Drug Delivery) and by End-User (Hospitals, Clinics, Diagnostic Centers, Home Care Settings, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Medical Devices & Supplies
Report Code: A01790
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Drug Delivery Technology Market

Request Now !

Drug delivery system is the process to administer therapeutic substance through common route of administration to achieve a therapeutic effect in humans or animals. Drugs delivery technology controls the rate and time of the drug released in the body thus improving the efficacy of the drug.

Increase in prevalence of chronic diseases, demand for biologics, and technological advancements majorly drive the market. In addition, increase in demand for biosimilar and generic drugs have boost the market growth. However, risk of needle-stick injuries and side effects of drugs restrict the market growth.

The report segments the drug delivery systems market based on route of administration, end-user, and geography. According to the route of administration, it is segmented as oral route, parenteral route, transdermal route, inhalation route, and nasal drug delivery. Parenteral route is further categorized into intramuscular, intravenous, intra-arterial, and subcutaneous route. By end-user, it is divided into clinics, diagnostic centers, and home care settings. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major key players operating in this market include Bayer AG, Johnson & Johnson, Novartis AG, Pfizer, Inc., 3M Company, and F. Hoffmann-La Roche Ltd.

Key Benefits for Stakeholders

  • This report offers an extensive analysis of the current trends and emerging estimations of the global drug delivery technology market, which assist to identify the prevailing opportunities.
  • Comprehensive analysis of all geographical regions is provided, along with factors that drive and restrict the market growth.
  • Quantitative analysis of the market is provided to showcase the financial scenario of the market.
  • The market conditions are comprehensively analyzed region- and country-wise.

 Drug Delivery Technology Market Report Highlights

Aspects Details
By Type
  • Oral Route
  • Parenteral Route
  • Transdermal Route
  • Inhalation Route
  • Nasal Drug Delivery
By End-User
  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Home Care Settings
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players E3D Elcam Drug Delivery Devices, Kindeva Drug Delivery, BD (Becton, Dickinson and Company), Ypsomed, West Pharmaceutical Services Inc., Baxter, Nemara, Medtronic, Gerresheimer AG
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Oral Route

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Parenteral Route

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Transdermal Route

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Inhalation Route

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Nasal Drug Delivery

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: DRUG DELIVERY TECHNOLOGY MARKET, BY END-USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End-user

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Clinics

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Diagnostic Centers

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Home Care Settings

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: DRUG DELIVERY TECHNOLOGY MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By End-user

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Drug Delivery Technology Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By End-user

      • 6.2.6. Canada Drug Delivery Technology Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By End-user

      • 6.2.7. Mexico Drug Delivery Technology Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By End-user

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By End-user

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Drug Delivery Technology Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By End-user

      • 6.3.6. Germany Drug Delivery Technology Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By End-user

      • 6.3.7. Italy Drug Delivery Technology Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By End-user

      • 6.3.8. Spain Drug Delivery Technology Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By End-user

      • 6.3.9. UK Drug Delivery Technology Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By End-user

      • 6.3.10. Russia Drug Delivery Technology Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By End-user

      • 6.3.11. Rest Of Europe Drug Delivery Technology Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By End-user

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By End-user

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Drug Delivery Technology Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By End-user

      • 6.4.6. Japan Drug Delivery Technology Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By End-user

      • 6.4.7. India Drug Delivery Technology Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By End-user

      • 6.4.8. South Korea Drug Delivery Technology Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By End-user

      • 6.4.9. Australia Drug Delivery Technology Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By End-user

      • 6.4.10. Thailand Drug Delivery Technology Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By End-user

      • 6.4.11. Malaysia Drug Delivery Technology Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By End-user

      • 6.4.12. Indonesia Drug Delivery Technology Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By End-user

      • 6.4.13. Rest of Asia Pacific Drug Delivery Technology Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By End-user

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By End-user

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Drug Delivery Technology Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By End-user

      • 6.5.6. South Africa Drug Delivery Technology Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By End-user

      • 6.5.7. Saudi Arabia Drug Delivery Technology Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By End-user

      • 6.5.8. UAE Drug Delivery Technology Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By End-user

      • 6.5.9. Argentina Drug Delivery Technology Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By End-user

      • 6.5.10. Rest of LAMEA Drug Delivery Technology Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By End-user

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Gerresheimer AG

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. BD (Becton, Dickinson And Company)

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Kindeva Drug Delivery

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Baxter

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. West Pharmaceutical Services Inc.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Ypsomed

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Medtronic

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Nemara

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. E3D Elcam Drug Delivery Devices

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL ROUTE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET FOR PARENTERAL ROUTE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL ROUTE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET FOR INHALATION ROUTE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET FOR NASAL DRUG DELIVERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET FOR CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA DRUG DELIVERY TECHNOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 17. U.S. DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 18. U.S. DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 19. CANADA DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 20. CANADA DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 21. MEXICO DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 22. MEXICO DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 23. EUROPE DRUG DELIVERY TECHNOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. EUROPE DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 25. EUROPE DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 26. FRANCE DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 27. FRANCE DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 28. GERMANY DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 29. GERMANY DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 30. ITALY DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. ITALY DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 32. SPAIN DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 33. SPAIN DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 34. UK DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 35. UK DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 36. RUSSIA DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. RUSSIA DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 38. REST OF EUROPE DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 39. REST OF EUROPE DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 40. ASIA-PACIFIC DRUG DELIVERY TECHNOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 41. ASIA-PACIFIC DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 42. ASIA-PACIFIC DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 43. CHINA DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 44. CHINA DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 45. JAPAN DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 46. JAPAN DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 47. INDIA DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 48. INDIA DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 49. SOUTH KOREA DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 50. SOUTH KOREA DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 51. AUSTRALIA DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 52. AUSTRALIA DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 53. THAILAND DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 54. THAILAND DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 55. MALAYSIA DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 56. MALAYSIA DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 57. INDONESIA DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 58. INDONESIA DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 59. REST OF ASIA PACIFIC DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 60. REST OF ASIA PACIFIC DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 61. LAMEA DRUG DELIVERY TECHNOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 62. LAMEA DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 63. LAMEA DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 64. BRAZIL DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 65. BRAZIL DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH AFRICA DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH AFRICA DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 68. SAUDI ARABIA DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 69. SAUDI ARABIA DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 70. UAE DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 71. UAE DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 72. ARGENTINA DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 73. ARGENTINA DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 74. REST OF LAMEA DRUG DELIVERY TECHNOLOGY, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 75. REST OF LAMEA DRUG DELIVERY TECHNOLOGY, BY END-USER, 2022-2032 ($MILLION)
  • TABLE 76. GERRESHEIMER AG: KEY EXECUTIVES
  • TABLE 77. GERRESHEIMER AG: COMPANY SNAPSHOT
  • TABLE 78. GERRESHEIMER AG: OPERATING SEGMENTS
  • TABLE 79. GERRESHEIMER AG: PRODUCT PORTFOLIO
  • TABLE 80. GERRESHEIMER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. BD (BECTON, DICKINSON AND COMPANY): KEY EXECUTIVES
  • TABLE 82. BD (BECTON, DICKINSON AND COMPANY): COMPANY SNAPSHOT
  • TABLE 83. BD (BECTON, DICKINSON AND COMPANY): OPERATING SEGMENTS
  • TABLE 84. BD (BECTON, DICKINSON AND COMPANY): PRODUCT PORTFOLIO
  • TABLE 85. BD (BECTON, DICKINSON AND COMPANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. KINDEVA DRUG DELIVERY: KEY EXECUTIVES
  • TABLE 87. KINDEVA DRUG DELIVERY: COMPANY SNAPSHOT
  • TABLE 88. KINDEVA DRUG DELIVERY: OPERATING SEGMENTS
  • TABLE 89. KINDEVA DRUG DELIVERY: PRODUCT PORTFOLIO
  • TABLE 90. KINDEVA DRUG DELIVERY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. BAXTER: KEY EXECUTIVES
  • TABLE 92. BAXTER: COMPANY SNAPSHOT
  • TABLE 93. BAXTER: OPERATING SEGMENTS
  • TABLE 94. BAXTER: PRODUCT PORTFOLIO
  • TABLE 95. BAXTER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. WEST PHARMACEUTICAL SERVICES INC.: KEY EXECUTIVES
  • TABLE 97. WEST PHARMACEUTICAL SERVICES INC.: COMPANY SNAPSHOT
  • TABLE 98. WEST PHARMACEUTICAL SERVICES INC.: OPERATING SEGMENTS
  • TABLE 99. WEST PHARMACEUTICAL SERVICES INC.: PRODUCT PORTFOLIO
  • TABLE 100. WEST PHARMACEUTICAL SERVICES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. YPSOMED: KEY EXECUTIVES
  • TABLE 102. YPSOMED: COMPANY SNAPSHOT
  • TABLE 103. YPSOMED: OPERATING SEGMENTS
  • TABLE 104. YPSOMED: PRODUCT PORTFOLIO
  • TABLE 105. YPSOMED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. MEDTRONIC: KEY EXECUTIVES
  • TABLE 107. MEDTRONIC: COMPANY SNAPSHOT
  • TABLE 108. MEDTRONIC: OPERATING SEGMENTS
  • TABLE 109. MEDTRONIC: PRODUCT PORTFOLIO
  • TABLE 110. MEDTRONIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. NEMARA: KEY EXECUTIVES
  • TABLE 112. NEMARA: COMPANY SNAPSHOT
  • TABLE 113. NEMARA: OPERATING SEGMENTS
  • TABLE 114. NEMARA: PRODUCT PORTFOLIO
  • TABLE 115. NEMARA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. E3D ELCAM DRUG DELIVERY DEVICES: KEY EXECUTIVES
  • TABLE 117. E3D ELCAM DRUG DELIVERY DEVICES: COMPANY SNAPSHOT
  • TABLE 118. E3D ELCAM DRUG DELIVERY DEVICES: OPERATING SEGMENTS
  • TABLE 119. E3D ELCAM DRUG DELIVERY DEVICES: PRODUCT PORTFOLIO
  • TABLE 120. E3D ELCAM DRUG DELIVERY DEVICES: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION
  • FIGURE 2. GLOBAL DRUG DELIVERY TECHNOLOGY MARKET
  • FIGURE 3. SEGMENTATION DRUG DELIVERY TECHNOLOGY MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN DRUG DELIVERY TECHNOLOGY MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDRUG DELIVERY TECHNOLOGY MARKET
  • FIGURE 11. DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. DRUG DELIVERY TECHNOLOGY MARKET FOR ORAL ROUTE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. DRUG DELIVERY TECHNOLOGY MARKET FOR PARENTERAL ROUTE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. DRUG DELIVERY TECHNOLOGY MARKET FOR TRANSDERMAL ROUTE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. DRUG DELIVERY TECHNOLOGY MARKET FOR INHALATION ROUTE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. DRUG DELIVERY TECHNOLOGY MARKET FOR NASAL DRUG DELIVERY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION, BY BY END-USER
  • FIGURE 18. DRUG DELIVERY TECHNOLOGY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. DRUG DELIVERY TECHNOLOGY MARKET FOR CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. DRUG DELIVERY TECHNOLOGY MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. DRUG DELIVERY TECHNOLOGY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. DRUG DELIVERY TECHNOLOGY MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: DRUG DELIVERY TECHNOLOGY MARKET
  • FIGURE 29. Top player positioning, 2022
  • FIGURE 30. GERRESHEIMER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. GERRESHEIMER AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. GERRESHEIMER AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. BD (BECTON, DICKINSON AND COMPANY): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. BD (BECTON, DICKINSON AND COMPANY): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. BD (BECTON, DICKINSON AND COMPANY): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. KINDEVA DRUG DELIVERY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. KINDEVA DRUG DELIVERY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. KINDEVA DRUG DELIVERY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. BAXTER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. BAXTER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. BAXTER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. WEST PHARMACEUTICAL SERVICES INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. WEST PHARMACEUTICAL SERVICES INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. WEST PHARMACEUTICAL SERVICES INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. YPSOMED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. YPSOMED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. YPSOMED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. MEDTRONIC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. MEDTRONIC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. NEMARA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. NEMARA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. NEMARA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. E3D ELCAM DRUG DELIVERY DEVICES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. E3D ELCAM DRUG DELIVERY DEVICES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. E3D ELCAM DRUG DELIVERY DEVICES: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Drug Delivery Technology Market

Start reading.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers